Kala Pharmaceuticals Inc (KALA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $89,480
Last updated: Nov 17, 2026 at 10:57 AM ET
Kala Pharmaceuticals Inc (KALA) Competitors
The companies most similar to Kala Pharmaceuticals are Karyopharm Therapeutics (KPTI), Kalaris Therapeutics (KLRS) and Kiora Pharmaceuticals (KPRX). By market cap, Kala Pharmaceuticals ranks 13th of the 13 companies on this page; Nkarta (NKTX) is the largest at $85.23M.
Peer Comparison
KALA's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Kala Pharmaceuticals (KALA) | $89480 | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Karyopharm Therapeutics Inc (KPTI) | $394660 | N/A | N/A | -153.3% | 64.5% | -11.9% | 0.00% |
| Kalaris Therapeutics, Inc. (KLRS) | $37.49M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Kiora Pharmaceuticals Inc (KPRX) | $5.44M | N/A | 6.2x | 0.0% | N/A | 0.0% | 0.00% |
| Kairos Pharma, Ltd. (KAPA) | $1.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CDT Equity Inc. (CDT) | $407550 | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Mink Therapeutics Inc (INKT) | $47.95M | N/A | 236.3x | 0.0% | N/A | 0.0% | 0.00% |
| Nkarta Inc (NKTX) | $85.23M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| OKYO Pharma Limited (OKYO) | $70.85M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Milestone Pharmaceuticals Inc (MIST) | $64.74M | N/A | 8.6x | 0.0% | -133.9% | -100.0% | 0.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $36.15M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| MAIA Biotechnology Inc. (MAIA) | $61.75M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Bioatla Inc (BCAB) | $2.89M | N/A | N/A | 0.0% | N/A | 31.6% | 0.00% |
| Peer median | $36.82M | N/A | 8.6x | 0.0% | -34.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Kala Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Karyopharm Therapeutics Inc (KPTI) | Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery... | KPTI competitors |
| Kalaris Therapeutics, Inc. (KLRS) | Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. | KLRS competitors |
| Kiora Pharmaceuticals Inc (KPRX) | Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for ocular diseases and neurodegenerative... | KPRX competitors |
| Kairos Pharma, Ltd. (KAPA) | Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. | KAPA competitors |
| CDT Equity Inc. (CDT) | Conduit Pharmaceuticals Inc. (CDT) is a clinical-stage biopharmaceutical company focused on creating innovative therapies for oncology and rare diseases... | CDT competitors |
| Mink Therapeutics Inc (INKT) | MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic... | INKT competitors |
| Nkarta Inc (NKTX) | Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. | NKTX competitors |
| OKYO Pharma Limited (OKYO) | OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye... | |
| Milestone Pharmaceuticals Inc (MIST) | Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular drugs. | MIST competitors |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human... | TELO competitors |
| MAIA Biotechnology Inc. (MAIA) | MAIA Biotechnology Inc. is an innovative biotechnology company focused on developing cutting-edge cancer therapies that significantly improve patient outcomes... | MAIA competitors |
| Bioatla Inc (BCAB) | BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapies for the treatment of various cancers. | BCAB competitors |
Frequently Asked Questions About KALA
Who are Kala Pharmaceuticals' main competitors?
The companies most similar to Kala Pharmaceuticals include Karyopharm Therapeutics (KPTI), Kalaris Therapeutics (KLRS), Kiora Pharmaceuticals (KPRX), Kairos Pharma (KAPA) and CDT Equity (CDT), listed from the closest match.
Who is Kala Pharmaceuticals' biggest competitor?
Nkarta (NKTX) is the largest of the similar companies at $85.23M; Karyopharm Therapeutics (KPTI) is the closest match by business profile, size, sector and industry.
How does KALA stock compare with its competitors?
KALA's net margin is 0.0% against a peer median of 0.0%.
Which of Kala Pharmaceuticals' competitors pays a higher dividend?
Kala Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Kala Pharmaceuticals bigger than its competitors?
No. Kala Pharmaceuticals is 13th by market cap among the 13 companies on this page; the largest is Nkarta (NKTX) at $85.23M.
KALA pages: Overview, Earnings, Financials, Competitors